Clarient CEO Ron Andrews to Present at J.P. Morgan 28th Annual Healthcare Conference in San Francisco

Will also Present at OneMedForum 2010 Emerging Healthcare Technologies Finance Conference

Jan 06, 2010, 06:00 ET from Clarient, Inc.

ALISO VIEJO, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Chief Executive Officer Ron Andrews is scheduled to make an investor presentation at the J.P. Morgan 28th Annual Healthcare Conference at 11:00 am PST on Thursday, January 14. The conference will be held January 11-14 at the Westin St. Francis Hotel in San Francisco.

Mr. Andrews will also present at the OneMedForum 2010 Emerging Healthcare Technologies Finance Conference at 2:15 p.m. PST on Wednesday, January 13. The conference will be held on January 12-14 at the Sir Francis Drake Hotel in Union Square, San Francisco.

A live webcast of each presentation will be available via a link provided at Archived replays of each presentation will also be available for a period of 90 days from the date of each presentation at

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides advanced oncology testing and diagnostic services. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, as well asleukemia/lymphoma.

    Matt Clawson
    Allen & Caron, Inc.
    (949) 474-4300

SOURCE Clarient, Inc.